Global Health Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Global Health Ltd filed with BSE on 05 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Global Health Limited (Medanta) reported consolidated income of INR13,262 million for Q1 FY27, up 26% year-on-year, with reported EBITDA of INR3,153 million, up 23% year-on-year. Management highlighted a sharp reduction in EBITDA losses at the newly commissioned Medanta Noida facility, from INR236 million in Q4 FY26 to INR49 million in Q1 FY27, alongside strong inpatient and outpatient volume growth across the network. The company also disclosed an expanded and revised Guwahati hospital project, now planned at 650 beds with an estimated cost of approximately INR9,700 million.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Consolidated income: INR13,262 million (Q1 FY27)
p. 4
“Consolidated income for the quarter was INR13,262 million, representing a healthy growth of 26% year-on-year.”
Pankaj Sahni, page 4 of the filed PDF · View the filing
EBITDA excluding Noida: INR3,201 million, margin 25.8% (Q1 FY27)
p. 4
“EBITDA, excluding Noida, witnessed a growth of 24% year-on-year to INR3,201 million, with margins improving to 25.8%, highlighting the continued strength of our core operating portfolio.”
Pankaj Sahni, page 4 of the filed PDF · View the filing
Reported EBITDA including Noida: INR3,153 million, margin 23.8% (Q1 FY27)
p. 4
“Reported EBITDA, including Noida stood at INR3,153 million, registering a healthy 23% year-on-year growth with EBITDA margins of 23.8%.”
Pankaj Sahni, page 4 of the filed PDF · View the filing
Profit after tax: INR1,573 million (Q1 FY27)
p. 4
“Profit after tax was INR1,573 million compared to INR1,590 million in Q1 FY26.”
Pankaj Sahni, page 4 of the filed PDF · View the filing
Inpatient volume growth: 28% (Q1 FY27 year-on-year)
p. 5
“Inpatient volumes increased by 28% year-on-year, while outpatient volumes grew by 34%, reflecting sustained demand across our specialties and the continued scale-up of our new facilities.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
Network occupancy: 63% (Q1 FY27)
p. 5
“Occupied bed days for the quarter increased by 21% with network occupancy remaining healthy at 63% on expanded bed capacity.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
ARPOB: INR70,244 (Q1 FY27)
p. 5
“Average revenue per occupied bed or ARPOB grew by 5% year-on-year to INR70,244, supported by favorable case mix, increasing contribution from high acuity specialties and improvement in operational efficiency.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
International patient revenue: INR782 million (Q1 FY27)
p. 5
“International patient revenue witnessed a growth of 23% year-on-year to INR782 million, reflecting strong growth despite current geopolitical tensions.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
OPD pharmacy revenue: INR609 million (Q1 FY27)
p. 5
“Our OPD pharmacy business also continued its strong growth trajectory with revenue increasing 51% year-on-year to INR609 million, supported by both hospital pharmacies and our expanding retail pharmacy network.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
Noida total income: INR855 million (Q1 FY27)
p. 5
“On the financial performance, Noida generated total income of INR855 million compared to INR525 million in Q4 FY26.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
Noida EBITDA loss: INR49 million (Q1 FY27)
p. 5
“More importantly, the EBITDA loss declined sharply from INR236 million in Q4 FY26 to only INR49 million in Q1 FY27.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
ARPP: INR201,891 (Q1 FY27)
p. 6
“For Q1 FY27, ARPP stood at INR201,891, broadly similar to the number achieved in the corresponding period last year, reflecting stable realization despite the continued ramp-up of newer and existing facilities.”
Pankaj Sahni, page 6 of the filed PDF · View the filing
Cluster 1 revenue: INR7,715 million (Q1 FY27)
p. 6
“Revenue from Cluster 1 stood at INR7,715 million, registering a year-on-year growth of 10%.”
Pankaj Sahni, page 6 of the filed PDF · View the filing
Cluster 1 EBITDA: INR1,858 million, margin 24.1% (Q1 FY27)
p. 6
“The EBITDA stood at INR1,858 million, reflecting a strong growth of 13% year-on-year with improved margins of 24.1% compared to 23.4% in the corresponding quarter.”
Pankaj Sahni, page 6 of the filed PDF · View the filing
Cluster 2 total income including Noida: INR4,983 million (Q1 FY27)
p. 6
“Including Noida, total income grew by 55% year-on-year to INR4,983 million, while EBITDA grew by 35% to INR1,272 million.”
Pankaj Sahni, page 6 of the filed PDF · View the filing
Cluster 2 ARPOB: INR61,742 (Q1 FY27)
p. 6
“ARPOB grew by a strong 9% to INR61,742, supported by favorable case mix and improved realization across the network.”
Pankaj Sahni, page 6 of the filed PDF · View the filing
Capex incurred in quarter: INR1,610 million (Q1 FY27)
p. 9
“In this quarter, we have done INR1,610 million of our capex.”
Yogesh Gupta, page 9 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Noida EBITDA breakeven — breakeven earlier than previous expectations
stated as an aspiration by Pankaj Sahni
p. 5
“Based on the current operating trajectory, we expect Noida to achieve EBITDA breakeven earlier than our previous expectations.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
Consolidated EBITDA margin
stated as an aspiration by Pankaj Sahni
p. 8
“So we don't give margin guidance as such.”
Pankaj Sahni, page 8 of the filed PDF · View the filing
Future capex requirement — INR4,850 crores
stated firmly by Yogesh Gupta
p. 9
“This INR4,850 crores is the future capex which needs to be incurred.”
Yogesh Gupta, page 9 of the filed PDF · View the filing
Indore 80-bed facility commissioning — come on board · towards the end of Q2, maybe early Q3
stated conditionally by Pankaj Sahni
p. 17
“we have a 80-bed facility, which we had acquired, which should come on board towards the end of Q2, maybe early Q3 in Indore.”
Pankaj Sahni, page 17 of the filed PDF · View the filing
Gurgaon operating room additions — almost 44, 45 operating rooms · coming quarter
stated firmly by Pankaj Sahni
p. 17
“we will probably in the coming quarter, activate 2 more operating rooms.”
Pankaj Sahni, page 17 of the filed PDF · View the filing
Retail pharmacy expansion rate — 15 or 20 pharmacies a quarter · next 4 to 6 quarters
stated as an aspiration by Pankaj Sahni
p. 14
“So if we were adding 10 pharmacies a quarter, maybe it will become 15 or 20.”
Pankaj Sahni, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said priorities remain consistent quarter to quarter, focused on clinical performance, Noida ramp-up, and adding clinical capabilities across existing hospitals.
Answered by Pankaj Sahni
Asked by Sucrit Patil: What are the top execution priorities and biggest risks in patient demand or competitive pressure?
p. 7
“So our operational and execution priorities don't change on a quarter-to-quarter basis. That's not how we necessarily think about the running of the organization.”
Pankaj Sahni, page 7 of the filed PDF · View the filing
CFO said margins have been stable and improving, cash flow generation remains strong, and leverage is low.
Answered by Yogesh Gupta
Asked by Sucrit Patil: What financial risks or challenges are anticipated, and how are margins, cash flow and balance sheet being managed?
p. 8
“We have a strong balance sheet with a very low leverage as on today, and we don't see any challenge on that side.”
Yogesh Gupta, page 8 of the filed PDF · View the filing
Management declined to give margin guidance but noted margins excluding Noida were already around 26% and expect operating leverage benefits as Noida losses reduce.
Answered by Pankaj Sahni
Asked by Parth Sodha: Can consolidated EBITDA margin move back to 25-26% as Noida matures?
p. 8
“So we don't give margin guidance as such.”
Pankaj Sahni, page 8 of the filed PDF · View the filing
CFO clarified the INR4,850 crore figure represents future capex still to be spent, with INR1,610 million spent in the quarter.
Answered by Yogesh Gupta
Asked by Abdulkader Puranwala: How much capex has been incurred against the planned expansion?
p. 9
“In this quarter, we have done INR1,610 million of our capex.”
Yogesh Gupta, page 9 of the filed PDF · View the filing
Management said Guwahati already has most approvals and construction underway, so such policy would not materially change its timeline.
Answered by Pankaj Sahni
Asked by Abdulkader Puranwala: Could a government policy on Tier 2/3 hospitals expedite Guwahati and Varanasi timelines?
p. 9
“I don't believe that there is any real need for any of these policies because we have already most of our approvals in place and construction activity is already commencing in Guwahati.”
Pankaj Sahni, page 9 of the filed PDF · View the filing
Management said the cancer specialty share actually increased year-on-year and attributed mix shifts to seasonality and classification of urology/GI cancers elsewhere.
Answered by Pankaj Sahni
Asked by Abdulkader Puranwala: Has the oncology specialty share declined due to CGHS provisions?
p. 10
“Our share of cancer, what we reported in our investor presentation has actually increased from 13.7% to 14.4% year-on-year.”
Pankaj Sahni, page 10 of the filed PDF · View the filing
Management said occupancy is roughly 30-40% but is not a meaningful metric given continuous bed additions.
Answered by Pankaj Sahni
Asked by Amey Chalke: What is the current occupancy level at Noida and will fixed costs increase further?
p. 11
“So I think the current occupancy at Noida is probably hovering somewhere in the 30% to 40% range.”
Pankaj Sahni, page 11 of the filed PDF · View the filing
Management said nearly all specialties are operating except liver transplant, and major equipment investment is largely complete.
Answered by Pankaj Sahni
Asked by Amey Chalke: Are all specialties operating at Noida or is further investment needed?
p. 11
“All the specialties are operating with the exception, I would say, of so far, we haven't done any liver transplant there.”
Pankaj Sahni, page 11 of the filed PDF · View the filing
Management said Cluster 2 (ex-Noida) inpatient volume growth was around 27%.
Answered by Pankaj Sahni
Asked by Tushar Manudhane: What was ex-Noida IPD volume growth year-on-year?
p. 12
“So for the ex-Noida, if you just look at our developing or what we now call as Cluster 2 hospitals, the IPD volume growth is around 27%.”
Pankaj Sahni, page 12 of the filed PDF · View the filing
Management said senior clinical attrition is negligible, though nursing and junior doctor attrition remains higher industry-wide.
Answered by Pankaj Sahni
Asked by Tushar Manudhane: Has attrition been observed at network or hospital level?
p. 13
“So we have seen very negligible to no attrition at any of our senior clinical levels across any of our hospitals.”
Pankaj Sahni, page 13 of the filed PDF · View the filing
Management explained the increase reflects expanded floor plate and doubled procedural capacity such as operating rooms and cath labs, not just bed count.
Answered by Pankaj Sahni
Asked by Vivek: Why has Guwahati capex increased significantly for the incremental beds?
p. 16
“So we have actually doubled the number of operating rooms that we were planning.”
Pankaj Sahni, page 16 of the filed PDF · View the filing
Management confirmed the CGHS hike is fully factored into the quarter but said the impact on overall revenue is not very significant given CGHS is roughly 10-12% of business.
Answered by Pankaj Sahni
Asked by Vivek: Has the CGHS rate hike benefit been fully reflected this quarter, and what is its scale?
p. 16
“So it's a long overdue hike. So there has been some positive impacts of it, but I think on the larger overall P&L of the company or overall revenue of the company, I don't think that this is moving it by several hundred basis points or anything like that.”
Pankaj Sahni, page 16 of the filed PDF · View the filing
Management declined to give margin guidance but noted Cluster 1 carries more corporate overhead cost, and Noida should benefit from operating leverage.
Answered by Pankaj Sahni
Asked by Raman KV: Can Cluster 2 hospitals sustain 30% margins, and will Noida reach similar margins as utilization ramps up?
p. 18
“So we don't give margin guidance, and I would not like to hazard a guess on what the margin would be in the future in Patna or Noida.”
Pankaj Sahni, page 18 of the filed PDF · View the filing
Risks flagged
Higher depreciation and finance costs from expanded asset base following Noida commissioning
p. 4
“Below EBITDA, the year-on-year comparison also reflects higher depreciation and finance costs associated with our expanded asset base, particularly following the commissioning and ramping up of Noida.”
Pankaj Sahni, page 4 of the filed PDF · View the filing
High attrition among nursing staff and junior doctors
p. 13
“Of course, we do have high attrition rates in nursing. Junior doctors continue to be at a high attrition rate for the industry, but we haven't seen any significant shift or any of our senior doctors so far at least moving out from the system.”
Pankaj Sahni, page 13 of the filed PDF · View the filing
Challenge of meeting rising healthcare demand with adequate quality supply
p. 13
“I think our real challenge will be, can we deliver the supply and more importantly, the high quality, ethical supply to meet that demand.”
Pankaj Sahni, page 13 of the filed PDF · View the filing
International patient revenue growth occurring despite geopolitical tensions
p. 5
“International patient revenue witnessed a growth of 23% year-on-year to INR782 million, reflecting strong growth despite current geopolitical tensions.”
Pankaj Sahni, page 5 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.